Titan Medical Inc. Completes Amadeus Composer(TM) Pre-Production Console and Video Tower

Marketwired

TORONTO, ONTARIO--(Marketwire - Dec. 1, 2011) - Titan Medical Inc. ("the Company") (TSX VENTURE:TMD.V - News) announced today that it has completed prototypes of the pre-production Surgeon Console and Video Tower, and Beta Patient Cart of its Amadeus Composer(TM) platform. The pre-production versions of the Surgeon Console and Video Tower are in the final phases of development and Titan plans to move forward to final design for manufacture and testing.

Craig Leon, Chief Executive Officer of Titan Medical Inc., commented, "I am extremely pleased with the efforts and dedication of our engineering team and development partners in completing the Console and Video Tower of Amadeus Composer(TM) on schedule. This marks a significant advancement in Titan Medical's development cycle. We are now committed to proceeding to our next major milestone of tissue and animal feasibility studies by the middle of 2012."

Amadeus Composer(TM) is a next generation surgical system that has a uniquely designed external robot and flexible instruments which allow surgeons to overcome constraints of surgical procedures in small to medium spaces. Amadeus Composer(TM) is designed for use in robotic surgery procedures such as thoracic (lung), ENT (ear, nose and throat), general surgical procedures as well as other surgical cases that are performed in very small and tight spaces. Other elements that make up the Amadeus(TM) Robotic Surgical System include communications, simulation systems and haptics.

About Titan Medical Inc.

Titan Medical Inc. is a Canadian public company (TSX VENTURE:TMD.V - News) focused on the development and commercialization of robotic surgical technologies. The Company is currently developing Amadeus Composer(TM), a surgical system that has a uniquely designed external robot and flexible instruments, and allows surgeons to overcome constraints of surgical procedures in small to medium spaces. Amadeus Maestro(TM), the Company's next generation 4-armed robotic surgical system with advanced communication and training, utilizes the Titan True Touch Technology(TM) and is targeted to surgical procedures in large spaces. Robotic surgery has developed over the past 10 years into a proven and growing method of treatment. The global robotic surgical market size is currently estimated to be approximately $1 billion and is estimated to grow to $5 billion by 2015 with potential for placement of 6,000 robotic surgical systems. The Company is researching and developing innovative technologies to empower surgeons to use robots in the operating room of the future. For more information, visit the Company's website at www.titanmedicalinc.com.

Forward Looking Statements

This news release contains "forward-looking statements" which reflect the current expectations of management of the Company's future development, milestones, performance, business prospects, opportunities and technological innovation. Wherever possible, words such as "may", "would", "could", "will", "anticipate", "believe", "plan", "expect", "intend", "estimate", "potential for" and similar expressions have been used to identify these forward-looking statements. These statements reflect management's current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance, achievements or technological innovation to be materially different from any future results, performance, achievements or technological innovation that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the "Risk Factors" section of the Company's Annual Information Form dated March 31, 2011 (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contacts

Craig Leon
Titan Medical Inc.
Chief Executive Officer
(416) 548-7522 (ext. 151)
cleon@titanmedicalinc.com
www.titanmedicalinc.com

Sherry Bertner
ICR, LLC
Managing Director
(646) 277-1247
Sherry.Bertner@icrinc.com